CA3136954A1 - Cyclic phosphate compounds - Google Patents
Cyclic phosphate compounds Download PDFInfo
- Publication number
- CA3136954A1 CA3136954A1 CA3136954A CA3136954A CA3136954A1 CA 3136954 A1 CA3136954 A1 CA 3136954A1 CA 3136954 A CA3136954 A CA 3136954A CA 3136954 A CA3136954 A CA 3136954A CA 3136954 A1 CA3136954 A1 CA 3136954A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- alkyl
- group
- cio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837137P | 2019-04-22 | 2019-04-22 | |
| US62/837,137 | 2019-04-22 | ||
| PCT/US2020/029149 WO2020219464A1 (en) | 2019-04-22 | 2020-04-21 | Cyclic phosphate compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3136954A1 true CA3136954A1 (en) | 2020-10-29 |
Family
ID=72941350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3136954A Pending CA3136954A1 (en) | 2019-04-22 | 2020-04-21 | Cyclic phosphate compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220220145A1 (https=) |
| EP (1) | EP3966221A4 (https=) |
| JP (2) | JP7661235B2 (https=) |
| KR (1) | KR20210154229A (https=) |
| CN (1) | CN113939526A (https=) |
| AU (1) | AU2020263283B2 (https=) |
| CA (1) | CA3136954A1 (https=) |
| MX (1) | MX2021012894A (https=) |
| WO (1) | WO2020219464A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102708995B1 (ko) | 2018-01-10 | 2024-09-23 | 누코리온 파마슈티컬스, 인코포레이티드. | 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물 |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| MX2022000573A (es) | 2019-07-17 | 2022-02-10 | Nucorion Pharmaceuticals Inc | Compuestos ciclicos de desoxirribonucleotido. |
| JP2023523415A (ja) * | 2020-04-21 | 2023-06-05 | リガンド・ファーマシューティカルズ・インコーポレイテッド | ヌクレオチドプロドラッグ化合物 |
| WO2021216431A1 (en) * | 2020-04-21 | 2021-10-28 | Ligand Pharmaceuticals, Inc. | Benzyloxy phosph(on)ate compounds |
| EP4232456A4 (en) * | 2020-10-21 | 2026-04-01 | Ligand Pharm Inc | COMPOUNDS OF ANTIVIRAL MEDICINES |
| WO2022245584A1 (en) * | 2021-05-17 | 2022-11-24 | Ligand Pharmaceuticals Incorporated | Unnatural configuration nucleotide prodrug compounds |
| CN118005694B (zh) * | 2023-01-06 | 2025-04-22 | 北京双鹤润创科技有限公司 | 一种环状核苷类似物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6023120B2 (ja) * | 1979-08-13 | 1985-06-05 | キッコーマン株式会社 | アデノシン−３′，５′−環状リン酸アルキルトリエステルの製造法 |
| DE3027279A1 (de) * | 1980-07-18 | 1982-05-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5834436A (en) * | 1993-04-09 | 1998-11-10 | The Regents Of The University Of California | Membrane-permeant second messengers |
| US5866548A (en) * | 1993-04-09 | 1999-02-02 | The Regents Of The University Of California | Caged membrane-permeant inositol phosphates |
| US5693521A (en) * | 1993-04-09 | 1997-12-02 | The Regents Of The University Of California | Membrane-permeant second messengers |
| WO2007027248A2 (en) * | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| CA2819041A1 (en) * | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| US9296778B2 (en) * | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| EP2906579B1 (en) * | 2012-10-08 | 2018-04-18 | Idenix Pharmaceuticals LLC. | 2'-chloro nucleoside analogs for hcv infection |
| JP2016501200A (ja) * | 2012-11-19 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ウイルス性疾患を処置するための２−アルキニル置換ヌクレオシド誘導体 |
| BR112015014457A2 (pt) * | 2012-12-21 | 2017-11-21 | Alios Biopharma Inc | composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c |
| US10202411B2 (en) * | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
| EP3471737B1 (en) * | 2016-06-20 | 2025-06-04 | Merck Sharp & Dohme LLC | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
| EP3661513A4 (en) | 2017-07-31 | 2021-07-14 | January Therapeutics, Inc. | ORGANOPHOSPHATE DERIVATIVES |
| CN111801339B (zh) | 2018-01-19 | 2025-06-24 | 纽科利制药公司 | 5-氟尿嘧啶化合物 |
| US20210038628A1 (en) * | 2018-03-02 | 2021-02-11 | January Therapeutics, Inc. | Nanoparticle compositions |
-
2020
- 2020-04-21 MX MX2021012894A patent/MX2021012894A/es unknown
- 2020-04-21 AU AU2020263283A patent/AU2020263283B2/en active Active
- 2020-04-21 US US17/604,681 patent/US20220220145A1/en active Pending
- 2020-04-21 CA CA3136954A patent/CA3136954A1/en active Pending
- 2020-04-21 KR KR1020217037884A patent/KR20210154229A/ko not_active Ceased
- 2020-04-21 CN CN202080038544.0A patent/CN113939526A/zh active Pending
- 2020-04-21 JP JP2021559729A patent/JP7661235B2/ja active Active
- 2020-04-21 WO PCT/US2020/029149 patent/WO2020219464A1/en not_active Ceased
- 2020-04-21 EP EP20796308.3A patent/EP3966221A4/en active Pending
-
2025
- 2025-04-02 JP JP2025060882A patent/JP2025106352A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7661235B2 (ja) | 2025-04-14 |
| AU2020263283A1 (en) | 2021-12-16 |
| EP3966221A1 (en) | 2022-03-16 |
| WO2020219464A1 (en) | 2020-10-29 |
| US20220220145A1 (en) | 2022-07-14 |
| KR20210154229A (ko) | 2021-12-20 |
| JP2025106352A (ja) | 2025-07-15 |
| EP3966221A4 (en) | 2023-05-24 |
| JP2022529321A (ja) | 2022-06-21 |
| AU2020263283B2 (en) | 2026-04-23 |
| MX2021012894A (es) | 2021-11-17 |
| CN113939526A (zh) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3136954A1 (en) | Cyclic phosphate compounds | |
| US10435429B2 (en) | 5-fluorouridine monophosphate cyclic triester compounds | |
| WO2019143860A1 (en) | 5-fluorouracil compounds | |
| EP4143199B1 (en) | Nucleotide prodrug compounds | |
| EP4335496A2 (en) | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | |
| EP4232456A1 (en) | Antiviral prodrug compounds | |
| JP2026032020A (ja) | ベンジルオキシリン酸エステル（ホスホン酸エステル）化合物 | |
| JP7625542B2 (ja) | 環状デオキシリボヌクレオチド化合物 | |
| AU2020315394B2 (en) | Cyclic deoxyribonucleotide compounds | |
| US20250188111A1 (en) | Cyclic phosphoramidate compounds | |
| RU2836016C2 (ru) | Циклические дезоксирибонуклеотидные соединения | |
| KR20260062967A (ko) | 사이클릭 포스페이트 화합물 | |
| HK40108726A (en) | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | |
| HK40063264A (en) | Cyclic deoxyribonucleotide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240422 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250325 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250325 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250514 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250912 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251222 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251222 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251222 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260331 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260331 |